Drawing on data from more than 2000 patients, the researchers of the retrospective study found that pulmonary function test results were associated with overall survival in non-small cell lung cancer (NSCLC).
New study findings are indicating that having good pulmonary function at the time of diagnosis of non-small cell lung cancer (NSCLC) may improve survival.
Drawing on data from more than 2000 patients in the Boston Lung Cancer Study, the researchers of the retrospective study found that pulmonary function test (PFT) results were associated with overall survival (OS).
In both univariate and multiple regression models, the researchers observed that patients in the highest quartiles (75%-100%) of forced expiratory volume in 1 second (FEV1), FEV1%, forced vital capacity (FVC), and FVC% had favorable mortality than patients in the lower quartiles.
“Based on the study finding, we recommend spirometry tests to be regularly conducted for risk stratification of lung cancer patients upon their diagnosis, regardless of their stage, which will further inform clinical decisions for appropriate treatment and care strategies to prolong their long-term survival,” highlighted the researchers.
“And spirometry might be extremely helpful for patients in advanced stages since a more personalized treatment strategy for them could better improve their survival outcomes. As pulmonary function could be an early biomarker for disease and aging, further research could dive into the observed role of pulmonary function in developing biomarkers and treatment targets for lung cancer prognosis," they added.
The researchers also explored how chronic obstructive pulmonary disease (COPD) impacted survival of NSCLC, finding that regardless of the stage, patients with COPD had worse survival. Median survival among patients without COPD was 75.8 months compared with 68.8 months among patients with GOLD stage 1 COPD, 58.6 months among patients with GOLD stage 2 COPD, 38.3 months among patients with GOLD stage 3 COPD, and 29.6 months among patients with GOLD stage 4 COPD.
Patients who had COPD were older, more likely to be male, have a lower body mass index, and more likely to be smokers compared with patients who did not have COPD. These patients also had a higher rate of squamous cell cancer (28% vs 17.65%), a lower rate of adenocarcinoma types (53.73% vs 64.51%), and they were more likely to receive surgery in addition to chemotherapy/radiation (21.17% vs 15.94%) compared with patients without COPD.
The group noted that their study did not include certain prognostic factors, such as performance status and physical activity, which could have introduced bias into their results. They cited other limitations of their study, including a potential of selection bias as patients with advanced stages of disease were less likely to receive PFTs.
“Therefore, we are cautious about the generalizability of the results to a general lung cancer population,” noted the researchers.
“However, we did perform several sensitivity analyses and observed similar dose–response relationships between baseline pulmonary function and overall survival as compared to the main results. Moreover, with our main interest focused on pulmonary function, the current findings were still useful for verifying the important role of the baseline pulmonary function in lung cancer prognosis," they concluded.
Reference
Zhai T, Li Y, Brown R, Lanuti M, Gainor J, Christiani D. Spirometry at diagnosis and overall survival in non-small cell lung cancer patients. Cancer Med. Published online May 12, 2022. doi:10.1002/cam4.4808
Use of AI Lets Health System Find Lung Cancer at Early Stages
March 8th 2025Artificial intelligence (AI) helps a Sarasota, Florida, health system catch lung nodules that appear on CT scans for patients treated for scores of conditions, allowing them to be referred for a possible lung cancer diagnosis.
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Study Finds Declining SCLC Incidence, but Stagnant Survival Rates
February 7th 2025SEER data show that small cell lung cancer (SCLS) incidence has steadily declined due to reduced smoking rates, but survival outcomes have seen only minimal improvement, underscoring the need for more effective treatments.
Read More
Emerging Therapies Shine Hope on Small Cell Lung Cancer Treatment
January 28th 2025Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address small cell lung cancer's aggressive nature and resistance to conventional therapy.
Read More